Board of Directors
Akihiro Ko - Elixirgen Therapeutics, Inc.
Minoru Ko, M.D., Ph.D. - Elixirgen Therapeutics, Inc.
Dr. Maiko Katadae, Ph.D. - Partner, UTEC (University of Tokyo Edge Capital Co., Ltd.) - focuses on the biotech and healthcare fields, taking charge of due diligence in life science technologies and investment operations for seed and early-stage venture enterprises. She invested in PeptiDream Inc. (listed in the TSE Mothers in June 2013 and the first section in December 2015) which utilizes special peptide manufacturing techniques to design new pharmaceutical drugs. She built management teams and was involved in business plans and development. She also served as an auditor.
Naonori Kurokawa - Partner, UTEC - joined UTEC in August 2009. He focuses on physical science investments: advanced material, nanotechnology, optoelectronics, imaging technology, and clean technology. Nori joined ARCH Venture Partners as an intern in February 2008. Prior to ARCH, he was with Samsung Electronics in South Korea, as a senior engineer. He was responsible for R&D of laser printer, specializing in imaging process and material development. Previously, he was a researcher at the Laboratory of Environmental Technology, Ricoh, Japan. He researched on imaging device, battery, and printing technology. He has three issued patents and seven pending patents in the US. Nori recieved his MBA at the University of Chicago Booth School of Business where he won the first place and the award for the most innovative plan in Edward L. Kaplan New Venture Challenge 2008. He earned his Ph.D. in applied physics from Osaka University in 2003.